Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02660034 · ClinicalTrials.gov registry record · Phase 1
The Safety, Pharmacokinetics and Antitumor Activity of BGB-A317 in Combination With BGB-290 in Participants With Advanced Solid Tumors
A Phase 1 study, sponsored by BeiGene.
- Completed
- Registry status
- Phase 1
- Development phase
- 229
- Enrollment target
NCT02660034: Completed Phase 1 study, sponsored by BeiGene.
NCT02660034 is a Phase 1 study that has completed, run by BeiGene. The registered enrollment target is 229 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (282% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02660034, a Phase 1 study, has completed, sponsored by BeiGene.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 229 participants
- Enrollment target
Study Summary
This trial studied the safety, pharmacokinetics, and antitumor activity of the anti-programmed cell death 1 (PD-1) monoclonal antibody (mAb) BGB-A317 (tislelizumab) in combination with the poly(adenosine diphosphate ribose) polymerase (PARP) inhibitor BGB-290 (pamiparib) in participants with advanced solid tumors.
Primary Outcome
An AE was defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study drug, whether considered related to study drug or not. All AEs reported are treatment-emergent, which was defined as having a reported onset time or worsening in severity on or after the date of the first dose of study treatment through 30 days after the last dose (permanent discontinuation of study treatment)
Interventions
- DRUG Pamiparib
- BIOLOGICAL Tislelizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 229 participants |
| Start Date | 2016-02-02 |
| Est. Completion | 2020-09-09 |
| Phase | Phase 1 |
What the finished NCT02660034 record still lists
NCT02660034 is an interventional study that assigns participants to a tested intervention. The registered 229 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (282% higher).
The record links to 0 conditions, and to 2 interventions - of which Pamiparib is the first listed.
NCT02660034 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02660034 about?
NCT02660034 is a clinical study titled "The Safety, Pharmacokinetics and Antitumor Activity of BGB-A317 in Combination With BGB-290 in Participants With Advanced Solid Tumors". This trial studied the safety, pharmacokinetics, and antitumor activity of the anti-programmed cell death 1 (PD-1) monoclonal antibody (mAb) BGB-A317 (tislelizumab) in combination with the poly(adenosine diphosphate ribose) polymerase (PARP) inhibitor BGB-290 (pamiparib) in participants with advance...
What is the current status of trial NCT02660034?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 229 participants. The study started on 2016-02-02. Estimated completion is 2020-09-09.
What interventions are being tested in trial NCT02660034?
The interventions under investigation include: Pamiparib (DRUG), Tislelizumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT02660034?
This trial is sponsored by BeiGene, which has 65 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02660034's enrollment target sits among peer trials
229 221st of 2000 higher than 1,780 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02710253 · 230 participants · Phase 2
Salvage Radiation Therapy in Treating Patients With Metastatic Cancer That Has Progressed After Systemic Immunotherapy
- NCT02777879 · 230 participants
Lung Microbiome and Inflammation in Early COPD
- NCT03824483 · 230 participants · Phase 2
Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL)
- NCT03833622 · 230 participants · NA
Shared Decision Making to Improve Goals of Care in the ED
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI